Kryptos Biotechnologies

Executive Summary

Kryptos Biotechnologies, a San Diego-based private company founded in 2018, is pioneering a rapid point-of-care PCR molecular diagnostic system for infectious diseases. The platform leverages proprietary photothermal heating technology to deliver results at the point of care, aiming to provide clinicians with actionable, cell-level insights in minutes rather than hours. This approach addresses a critical gap in decentralized diagnostics, where speed and accuracy are paramount for managing infectious disease outbreaks and improving patient outcomes. As a diagnostics-focused developer, Kryptos is positioned to compete in the expanding market for rapid, portable molecular testing, especially in settings lacking traditional laboratory infrastructure. The company’s technology has the potential to disrupt the traditional PCR testing paradigm by reducing instrument complexity and cost while maintaining high sensitivity and specificity. With the global point-of-care diagnostics market projected to grow substantially, Kryptos stands to benefit from increasing demand for rapid testing in hospitals, clinics, and remote settings. While the company has not disclosed funding or regulatory milestones, its innovative approach suggests strong upside if clinical validation and commercialization efforts succeed. Kryptos will need to navigate regulatory pathways (e.g., FDA clearance) and establish manufacturing scalability to capture market share in a competitive landscape that includes players like Cepheid and Abbott.

Upcoming Catalysts (preview)

• Q4 2026FDA Emergency Use Authorization or 510(k) Clearance for Initial Test60% success
• Q2 2027Strategic Partnership with Hospital System or Diagnostic Distributor70% success
• Q3 2026Series B or Series C Funding Round50% success